{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:40:18Z","timestamp":1780393218962,"version":"3.54.1"},"reference-count":43,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>This study aims to assess the reporting of antimicrobial-related adverse drug events (ADEs) in Jordan between 2003 and 2022. Data regarding the antimicrobial-related ADEs were extracted from the WHO\u2019s global database (VigiBase) by the Rational Drug Use and Pharmacovigilance Department at the Jordan Food and Drug Administration (JFDA). A total of 279 Individual Case Safety Reports (ICSRs) were recorded. The number of ICSRs increased from 2019 onwards (219 out of 279 cases). This increase in the reported ADEs was influenced by the actions of the JFDA, including the introduction of electronic reporting forms, updating the national pharmacovigilance guidelines, which encouraged adverse drug reactions reporting, the implementation of the AMR-national action plan, the encouragement to report due to COVID-19 vaccine, and the continuous awareness campaigns and training programs. Skin and subcutaneous tissue disorders (n = 105; 19.48%) were the most reported antimicrobial-related ADEs. The highest number of ADEs was reported for tetracyclines (n = 101; 18.74%) followed by fluoroquinolones (n = 54; 10.02%), third-generation cephalosporines (n = 48; 8.9%), and carbapenems (n = 42; 7.79%). From the top 10 consumed antibiotics, the number of ADEs in patients who consumed Watch group antibiotics (97 ADEs) was higher than those who consumed Access group antibiotics (28 ADEs). The findings highlight the need to monitor and rationalize the use of Watch antibiotics. Enhanced reporting of antimicrobial-related adverse drug reactions is needed to inform antimicrobial stewardship and improve the pharmacovigilance system in Jordan.<\/jats:p>","DOI":"10.3390\/antibiotics12030624","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T07:09:31Z","timestamp":1679468971000},"page":"624","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Reporting Antimicrobial-Related Adverse Drug Events in Jordan: An Analysis from the VigiBase Database"],"prefix":"10.3390","volume":"12","author":[{"given":"Nizar Mahmoud","family":"Mhaidat","sequence":"first","affiliation":[{"name":"Clinical Pharmacy Department, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan"},{"name":"Jordan Food and Drug Administration (JFDA), Amman 11181, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayer","family":"Al-Azzam","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayaa Abdallah","family":"Banat","sequence":"additional","affiliation":[{"name":"Jordan Food and Drug Administration (JFDA), Amman 11181, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaber Mohammad","family":"Jaber","sequence":"additional","affiliation":[{"name":"Jordan Food and Drug Administration (JFDA), Amman 11181, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8440-8585","authenticated-orcid":false,"given":"Mohammad","family":"Araydah","sequence":"additional","affiliation":[{"name":"Princess Basma Teaching Hospital, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2466-4763","authenticated-orcid":false,"given":"Osama Y.","family":"Alshogran","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8148-7612","authenticated-orcid":false,"given":"Mamoon A.","family":"Aldeyab","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield HD1 3DH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"key":"ref_1","first-page":"147","article-title":"Pharmacist\u2019s knowledge, practice and attitudes toward pharmacovigilance and adverse drug reactions reporting process","volume":"23","author":"Suyagh","year":"2015","journal-title":"Saudi Pharm. J. SPJ Off. Publ. Saudi Pharm. Soc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1023\/A:1015570104121","article-title":"Hospitalisations caused by adverse drug reactions (ADR): A meta-analysis of observational studies","volume":"24","author":"Beijer","year":"2002","journal-title":"Pharm. World Sci. PWS"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1056\/NEJM199102073240605","article-title":"The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II","volume":"324","author":"Leape","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_4","unstructured":"Committee of Experts on Management of Safety and Quality in Health Care (CEMSQHC) (2005). Expert Group on Safe Medication Practices: Glossary of Terms Related to Patient and Medication Safety, Council of Europe."},{"key":"ref_5","first-page":"321","article-title":"Reducing adverse drug events: Lessons from a breakthrough series collaborative","volume":"26","author":"Leape","year":"2000","journal-title":"Jt. Comm. J. Qual. Improv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/pds.667","article-title":"Adverse drug reactions as a cause for admissions to a department of internal medicine","volume":"11","author":"Boman","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1365-2125.2007.03064.x","article-title":"Incidence of fatal adverse drug reactions: A population based study","volume":"65","author":"Wester","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_8","unstructured":"World Health Organization (2023, March 16). Planning for the Global Patient Safety Challenge on Medication Safety, Available online: https:\/\/www.who.int\/patientsafety\/medication-safety\/planning-consultation\/en\/."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients","volume":"329","author":"Pirmohamed","year":"2004","journal-title":"BMJ"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1365-2125.1998.00667.x","article-title":"Frequency and cost of serious adverse drug reactions in a department of general medicine","volume":"45","author":"Moore","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_11","unstructured":"WHO (2023, March 08). What is Pharmacovigilance?, Available online: https:\/\/www.who.int\/teams\/regulation-prequalification\/regulation-and-safety\/pharmacovigilance#:~:text=Pharmacovigilance%20is%20the%20science%20and,they%20are%20authorized%20for%20use."},{"key":"ref_12","first-page":"237","article-title":"Pharmacovigilance in india: Perspectives and prospects","volume":"3","author":"Kumar","year":"2013","journal-title":"J. Drug Deliv. Ther."},{"key":"ref_13","unstructured":"Kohn, L.T., Corrigan, J.M., and Donaldson, M.S. (2000). To Err is Human: Building a Safer Health System."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies","volume":"279","author":"Lazarou","year":"1998","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00228-021-03238-2","article-title":"Hospitalizations and deaths related to adverse drug events worldwide: Systematic review of studies with national coverage","volume":"78","author":"Silva","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e1040","DOI":"10.1097\/PTS.0000000000000679","article-title":"Adverse Drug Events Detected by Clinical Pharmacists in an Emergency Department: A Prospective Monocentric Observational Study","volume":"17","author":"Laureau","year":"2021","journal-title":"J. Patient Saf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s11096-019-00925-0","article-title":"Preventability analysis of adverse drug reactions in a Jordanian hospital: A prospective observational study","volume":"41","author":"Basheti","year":"2019","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1345\/aph.1H658","article-title":"Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care","volume":"41","author":"Thomsen","year":"2007","journal-title":"Ann. Pharmacother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1093\/ajhp\/59.18.1742","article-title":"Identifying clinically significant preventable adverse drug events through a hospital\u2019s database of adverse drug reaction reports","volume":"59","author":"Winterstein","year":"2002","journal-title":"Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1365-2125.2010.03751.x","article-title":"Emergency re-admissions to hospital due to adverse drug reactions within 1 year of the index admission","volume":"70","author":"Davies","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/picr.PICR_4_18","article-title":"Assessing knowledge, attitude, and practices of health-care providers toward pharmacovigilance and adverse drug reaction reporting at a comprehensive cancer center in Jordan","volume":"10","author":"Hanoun","year":"2019","journal-title":"Perspect. Clin. Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Scripcaru, G., Mateus, C., and Nunes, C. (2017). Adverse drug events-Analysis of a decade. A Portuguese case-study, from 2004 to 2013 using hospital database. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0178626"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11606-010-1518-3","article-title":"Incidence of adverse drug events and medication errors in Japan: The JADE study","volume":"26","author":"Morimoto","year":"2011","journal-title":"J. Gen. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1001\/jamainternmed.2017.1938","article-title":"Association of Adverse Events With Antibiotic Use in Hospitalized Patients","volume":"177","author":"Tamma","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1007\/s11606-018-4430-x","article-title":"National Estimates of Emergency Department Visits for Antibiotic Adverse Events Among Adults-United States, 2011\u20132015","volume":"33","author":"Geller","year":"2018","journal-title":"J. Gen. Intern. Med."},{"key":"ref_26","unstructured":"(2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet, 399, 629\u2013655."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40264-015-0387-4","article-title":"Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase\u00ae","volume":"39","author":"Ampadu","year":"2016","journal-title":"Drug Saf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00228-020-03035-3","article-title":"Antimicrobial stewardship: Can we add pharmacovigilance networks to the toolbox?","volume":"77","author":"Habarugira","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/510393","article-title":"Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship","volume":"44","author":"Dellit","year":"2007","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/QCO.0000000000000604","article-title":"Antibiotics and adverse events: The role of antimicrobial stewardship programs in \u2018doing no harm\u2019","volume":"32","author":"Bauer","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11532410-000000000-00000","article-title":"WHO\u2019s international drug monitoring--the formative years, 1968\u20131975: Preparatory, pilot and early operational phases","volume":"33","author":"Venulet","year":"2010","journal-title":"Drug Saf."},{"key":"ref_32","unstructured":"UMC (2023, February 07). The WHO Programme for International Drug Monitoring. Available online: https:\/\/who-umc.org\/about-the-who-programme-for-international-drug-monitoring\/."},{"key":"ref_33","unstructured":"HMA (2023, February 07). European Medecines Agency, Guideline on Good Pharmacovigilance Practices (GVP), Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/pharmacovigilance\/good-pharmacovigilance-practices."},{"key":"ref_34","unstructured":"UMC (Uppsala Monitoring Centre) (2023, February 03). Available online: https:\/\/who-umc.org\/vigibase\/."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Al-Azzam, S., Mhaidat, N.M., Banat, H.A., Alfaour, M., Ahmad, D.S., Muller, A., Al-Nuseirat, A., Lattyak, E.A., Conway, B.R., and Aldeyab, M.A. (2021). An Assessment of the Impact of Coronavirus Disease (COVID-19) Pandemic on National Antimicrobial Consumption in Jordan. Antibiotics, 10.","DOI":"10.3390\/antibiotics10060690"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/jep.12683","article-title":"Health care professionals knowledge and perception of pharmacovigilance in a tertiary care teaching hospital in Amman, Jordan","volume":"23","year":"2017","journal-title":"J. Eval. Clin. Pract."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/1574884713666180308151805","article-title":"Knowledge, Attitudes, and Practices of Pharmacovigilance and ADRs Spontaneous Reporting Among Pediatricians and Pediatric Residents in Jordan","volume":"13","author":"Mukattash","year":"2018","journal-title":"Curr. Clin. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/inthealth\/ihy029","article-title":"A survey on the knowledge, attitudes and practices of physicians towards pharmacovigilance in Jordanian health centres","volume":"10","author":"Shroukh","year":"2018","journal-title":"Int. Health"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Thomas, F., Abiri, O.T., Komeh, J.P., Conteh, T.A., Bah, A.J., Kanu, J.S., Terry, R., Abrahamyan, A., Thekkur, P., and Zachariah, R. (2022). Inconsistent Country-Wide Reporting of Adverse Drug Reactions to Antimicrobials in Sierra Leone (2017\u20132021): A Wake-Up Call to Improve Reporting. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19063264"},{"key":"ref_40","unstructured":"(2023, January 28). Antimicrobial Resistance\u2014An Overlooked Adverse Event. Available online: https:\/\/www.who-mc.org\/media\/2775\/web_uppsalareports_issue74.pdf."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/pds.5249","article-title":"Pharmacovigilance network as an additional tool for the surveillance of antimicrobial resistance","volume":"30","author":"Habarugira","year":"2021","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_42","unstructured":"Rational Drug Use & Pharmacovigilance Department (2023, January 28). Jordan Pharmacovigilance Database Analysis. Available online: http:\/\/www.jfda.jo\/EchoBusV3.0\/SystemAssets\/Documents\/AR\/DRUGD\/Pharmacovigilance%20Booklet.pdf."},{"key":"ref_43","unstructured":"MedDRA (2023, January 24). Medical Dictionary for Regulatory Activities. Available online: https:\/\/www.meddra.org\/how-to-use\/basics\/hierarchy."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/3\/624\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:00:02Z","timestamp":1760122802000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/12\/3\/624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["antibiotics12030624"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics12030624","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]}}}